[{"orgOrder":0,"company":"Endo Pharm","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.54000000000000004,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Isofol Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"PALADIN LABS \/ PALADIN LABS","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ PALADIN LABS"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Aliskiren","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo Pharm \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"PALADIN LABS \/ Paladin Labs","highestDevelopmentStatusID":"11","companyTruncated":"PALADIN LABS \/ Paladin Labs"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cch-Aaes","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C.","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C."},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Endo International"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cch-Aaes","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Undisclosed","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tiopronin","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PALADIN LABS \/ Paladin Labs","highestDevelopmentStatusID":"11","companyTruncated":"PALADIN LABS \/ Paladin Labs"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymorphone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PALADIN LABS \/ Paladin Labs","highestDevelopmentStatusID":"9","companyTruncated":"PALADIN LABS \/ Paladin Labs"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Immunology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Aliskiren","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Endo Pharm"}]
Find Clinical Drug Pipeline Developments & Deals by Endo Pharm
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
